Micro Aftermath Archived

ABBV acquisition of Apogee Therapeutics

Activity declining — narrative losing relevance.

Score 0.3

Velocity ▲ 0.0

Articles 14

Sources 2

Sentiment Timeline

Event Timeline

Jul 20, 2026 How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? Neutral

Jul 12, 2026 AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee … Bullish

Jun 29, 2026 AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive … Bullish

Jun 27, 2026 AbbVie (ABBV) to Acquire Apogee Therapeutics Bullish

Jun 26, 2026 Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook Bullish

Jun 25, 2026 AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 … Bullish

Jun 24, 2026 The $11 Billion Reason Abbvie Stock Is Up Today Bullish

Jun 22, 2026 Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout … Bullish

Jun 21, 2026 This Healthcare Stock Trades at a Richer Valuation Than Nvidia. Could It … Neutral

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? Nasdaq · Jul 20, 2026 Mixed AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make … Nasdaq · Jul 12, 2026 Mixed AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? Nasdaq · Jun 29, 2026 Mixed AbbVie (ABBV) to Acquire Apogee Therapeutics Yahoo Finance · Jun 27, 2026 Mixed Is AbbVie a Buy After Its Purchase of Apogee? Yahoo Finance · Jun 26, 2026 Mixed Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook Yahoo Finance · Jun 26, 2026 Mixed AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could … Yahoo Finance · Jun 25, 2026 Mixed Apogee Therapeutics (APGE) Hits Fresh High on AbbVie $10.9B Merger Yahoo Finance · Jun 24, 2026 Bearish The $11 Billion Reason Abbvie Stock Is Up Today Yahoo Finance · Jun 24, 2026 Bearish AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load … Nasdaq · Jun 22, 2026 Mixed Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer Nasdaq · Jun 22, 2026 Mixed AbbVie to acquire Apogee Therapeutics in $10.9B deal Yahoo Finance · Jun 22, 2026 Mixed

🤖 AI Overview

On June 22, AbbVie Inc. (NYSE:ABBV) announced a definitive agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for approximately $10.9 billion in an all-cash transaction, valuing APGE shares at over $135 each. This acquisition adds a pipeline of clinical-stage therapies for inflammatory and immunological diseases to AbbVie's portfolio, including atopic dermatitis and asthma treatments.

The deal drives a significant surge in APGE's stock price, up 46.66% on June 22, and a 6.25% increase in ABBV shares the same day. It also strengthens AbbVie's long-term growth outlook, leading Canaccord to raise its price target on ABBV to $273 and reiterate a 'Buy' rating. AbbVie, already among the top blue-chip stocks with growing dividends, further solidifies its position in the immunology space.

Next, investors should watch for the deal's closure, expected in Q4 2022 or early 2023. Additionally, the progress of Apogee's pipeline, particularly its lead asset zumilokibart, will be crucial. AbbVie's Q2 earnings, scheduled for late July, may provide further insights into the company's strategic vision post-acquisition.

AI Overview as of Jun 29, 2026

Timeline

Last UpdatedJun 21, 2026

ABBV acquisition of Apogee Therapeutics

Sentiment Timeline

Event Timeline

Related Articles